Drug Index

ELITEK

Generic: RASBURICASE

Review priority: STANDARD Marketing status: Prescription

Route: INTRAVENOUS
Class: General Medications
Safety profile: routine
Latest regulatory update: 12 Dec 2019, 12:00 am (UTC)

Structured Monograph

Approval overview ELITEK is listed in Drugs@FDA under application 103946 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient RASBURICASE Form and strength VIAL; INTRAVENOUS - 1.5MG/VIAL Sponsor SANOFI SYNTHELABO Submission history Latest submission status date: 2019-12-12 00:00:00. Submission type: SUPPL.